The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes.
Aldosterone binds to the mineralocorticoid receptor (MR) and exerts pleiotropic effects beyond enhancing renal sodium reabsorption. Excessive mineralocorticoid signaling is deleterious during the evolution of cardiac failure, as evidenced by the benefits provided by adding MR antagonists (MRA) to st...
Main Authors: | Basile Gravez, Antoine Tarjus, Ruben Jimenez-Canino, Soumaya El Moghrabi, Smail Messaoudi, Diego Alvarez de la Rosa, Frederic Jaisser |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3767808?pdf=render |
Similar Items
-
Torasemide – loop diuretic with specific effects
by: V. M. Gorbunov, et al.
Published: (2006-10-01) -
Pharmacogenetics as a Way for Personalizing Diuretic Therapy: Focus on Torasemide
by: N. M. Gafurova, et al.
Published: (2021-03-01) -
The Mineralocorticoid Receptor on Smooth Muscle Cells Promotes Tacrolimus-Induced Renal Injury in Mice
by: Stefanny M. Figueroa, et al.
Published: (2023-04-01) -
Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury
by: Toshifumi Nakamura, et al.
Published: (2022-06-01) -
Pathophysiological Roles of Aldosterone and Mineralocorticoid Receptor in the Kidney
by: Kazi Rafiq, et al.
Published: (2011-01-01)